The observed high endogenous expression of CLU in the MDA-PCa-2b cell line, derived from an AA patient, could suggest that downstream effects of GR signaling such as the upregulation of therapy-resistance associated genes may be exaggerated in AA PCa patients. The gene discussed is CLU; the disease is posterior cortical atrophy.